Epidemiology of Breast Cancer in France
Author(s)
Simona Bara, Epidemiologist1, Olivier Tredan, Physician2, Yann Delpech, Physician3, Danko Stamenic, Statistician4, Manoel Moreau, RWE expert5, Majda Le Foll-Elfounini, Project Manager4, Marie Lotz, Medical advisor4, Laura Mansi, Physician6.
1Centre Hospitalier du Cotentin, Cherbourg-en-Cotentin, France, 2Centre Leon Berard, Lyon, France, 3Centre Antoine Lacassagne, Nice, France, 4Roche SAS, Boulogne-Billancourt, France, 5ROCHE SAS, Boulogne Billancourt, France, 6CHRU Jean Minjoz, Besançon, France.
1Centre Hospitalier du Cotentin, Cherbourg-en-Cotentin, France, 2Centre Leon Berard, Lyon, France, 3Centre Antoine Lacassagne, Nice, France, 4Roche SAS, Boulogne-Billancourt, France, 5ROCHE SAS, Boulogne Billancourt, France, 6CHRU Jean Minjoz, Besançon, France.
OBJECTIVES: To estimate breast cancer (BC) incidence by subtype, stage at diagnosis (early, de novo metastatic) and age group from the French National Claims Database (SNDS).
METHODS: The SNDS covers around 98% of the total French population. Data was extracted from Magellan, a database containing 5 years of SNDS data. All French women aged ≥18 years newly diagnosed with BC during 2019 and 2020 were identified by a marker of BC management. HER2+ and HR+ patients were respectively identified by HER2+ targeted therapy and endocrine therapy reimbursement. Triple Negative BC (TNBC) patients and HR+ patients with visceral crisis cannot be identified because of the lack of tracking drugs. One year historical period has been used and 1,5 years follow-up to distinguish early and metastatic stages
RESULTS: In total, there were 67 881 new cases of BC in France in 2019 and 59 006 in 2020 implying a 13% reduction in the yearly BC incidence. The mean age at BC diagnosis was 62.1 years in both 2019 and 2020.HER2+ BC incidence was 1 813 (2,6% of total new BC cases) in 2019 and 1 308 (2,2%) in 2020 with the mean age at diagnosis of 57.4 and 57.8 years in 2019 and 2020, respectively.HR+ BC incidence was 47 852 (70,4% of total new BC cases) in 2019 and 43 270 (73,3%) in 2020 with the mean age at diagnosis of 62.3 and 62.4 years, respectively. Among this population, around 90% were treated at an early stage. Complementary analysis are ongoing and will be presented in the corresponding poster.
CONCLUSIONS: Mean age remains stable. HER2+ population seems younger. 2020 being the Covid period potentially reduced BC screening. A second analysis including years up to 2023 is planned to get additional information on BC Evolution.
METHODS: The SNDS covers around 98% of the total French population. Data was extracted from Magellan, a database containing 5 years of SNDS data. All French women aged ≥18 years newly diagnosed with BC during 2019 and 2020 were identified by a marker of BC management. HER2+ and HR+ patients were respectively identified by HER2+ targeted therapy and endocrine therapy reimbursement. Triple Negative BC (TNBC) patients and HR+ patients with visceral crisis cannot be identified because of the lack of tracking drugs. One year historical period has been used and 1,5 years follow-up to distinguish early and metastatic stages
RESULTS: In total, there were 67 881 new cases of BC in France in 2019 and 59 006 in 2020 implying a 13% reduction in the yearly BC incidence. The mean age at BC diagnosis was 62.1 years in both 2019 and 2020.HER2+ BC incidence was 1 813 (2,6% of total new BC cases) in 2019 and 1 308 (2,2%) in 2020 with the mean age at diagnosis of 57.4 and 57.8 years in 2019 and 2020, respectively.HR+ BC incidence was 47 852 (70,4% of total new BC cases) in 2019 and 43 270 (73,3%) in 2020 with the mean age at diagnosis of 62.3 and 62.4 years, respectively. Among this population, around 90% were treated at an early stage. Complementary analysis are ongoing and will be presented in the corresponding poster.
CONCLUSIONS: Mean age remains stable. HER2+ population seems younger. 2020 being the Covid period potentially reduced BC screening. A second analysis including years up to 2023 is planned to get additional information on BC Evolution.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EPH81
Topic
Epidemiology & Public Health, Real World Data & Information Systems
Disease
Oncology